Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by Shahid Beheshti University of Medical Sciences.
Recruitment status was  Recruiting
Information provided by:
Shahid Beheshti University of Medical Sciences Identifier:
First received: August 30, 2006
Last updated: June 25, 2008
Last verified: June 2008
To evaluate the effect of intravitreal bevacizumab on the course of diabetic retinopathy in cases with the signs of active progressive PDR

Condition Intervention Phase
Diabetic Retinopathy
Drug: bevacizumab
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Shahid Beheshti University of Medical Sciences:

Primary Outcome Measures:
  • Regression of diabetic retinopathy
  • visual acuity

Secondary Outcome Measures:
  • neovascularization
  • fibrous proliferation
  • traction retinal detachment
  • vitreous hemorrhage
  • pan retinal photocoagulation

Study Start Date: March 2006
Arms Assigned Interventions
Experimental: I Drug: bevacizumab


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cases of active progressive PDR with history of scatter laser photocoagulation

Exclusion Criteria:

  • history of vitrectomy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00370721

Contact: Hamid Ahmadieh, MD +98 21 22585952

Iran, Islamic Republic of
Hamid Ahmadieh, MD Recruiting
Tehran, Iran, Islamic Republic of, 16666
Contact: Hamid Ahmadieh, MD    +98 21 22585952   
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Principal Investigator: Hamid Ahmadieh, MD Ophthalmic Research Center of Shaheed Beheshti Medical University
  More Information Identifier: NCT00370721     History of Changes
Other Study ID Numbers: 8538 
Study First Received: August 30, 2006
Last Updated: June 25, 2008
Health Authority: Iran: Ethics Committee

Keywords provided by Shahid Beheshti University of Medical Sciences:
Proliferative diabetic retinopathy(PDR)
Pan retinal photocoagulation (PRP)
Vitreous hemorrhage
Traction retinal detachment
Neovascularization on disc (NVD)
Neovascularization elsewhere (NVE)
Fibrous proliferation on disc (FPD)
Fibrous proliferaiton elsewhere (FPE)

Additional relevant MeSH terms:
Eye Diseases
Diabetes Complications
Diabetes Mellitus
Retinal Diseases
Diabetic Retinopathy
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Endocrine System Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on October 25, 2016